|
Name |
14-Methoxytajixanthone-25-acetate
|
Molecular Formula | C29H31HoO8 | |
IUPAC Name* |
[1-acetyloxy-8-[1-(3,3-dimethyloxiran-2-yl)-1-methoxyethyl]-11-hydroxy-5-methyl-12-oxo-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-3-yl]holmium
|
|
SMILES |
C=C(C)C1C([Ho])Oc2c(C)cc3oc4c(C(C)(OC)C5OC5(C)C)ccc(O)c4c(=O)c3c2C1OC(C)=O
|
|
InChI |
InChI=1S/C29H31O8.Ho/c1-13(2)16-12-34-24-14(3)11-19-21(22(24)25(16)35-15(4)30)23(32)20-18(31)10-9-17(26(20)36-19)29(7,33-8)27-28(5,6)37-27;/h9-12,16,25,27,31H,1H2,2-8H3;/t16-,25+,27+,29+;/m0./s1
|
|
InChIKey |
KMFAZXHWFHEGJU-WFPCKFNCSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 672.49 | ALogp: | 5.1 |
HBD: | 1 | HBA: | 8 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 107.7 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.127 |
Caco-2 Permeability: | -4.898 | MDCK Permeability: | 0.00001400 |
Pgp-inhibitor: | 0.987 | Pgp-substrate: | 0.072 |
Human Intestinal Absorption (HIA): | 0.56 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.1 |
Blood-Brain-Barrier Penetration (BBB): | 0.036 | Plasma Protein Binding (PPB): | 83.35% |
Volume Distribution (VD): | 1.364 | Fu: | 9.31% |
CYP1A2-inhibitor: | 0.045 | CYP1A2-substrate: | 0.942 |
CYP2C19-inhibitor: | 0.19 | CYP2C19-substrate: | 0.616 |
CYP2C9-inhibitor: | 0.754 | CYP2C9-substrate: | 0.254 |
CYP2D6-inhibitor: | 0.41 | CYP2D6-substrate: | 0.346 |
CYP3A4-inhibitor: | 0.447 | CYP3A4-substrate: | 0.765 |
Clearance (CL): | 1.845 | Half-life (T1/2): | 0.045 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.954 |
Drug-inuced Liver Injury (DILI): | 0.974 | AMES Toxicity: | 0.692 |
Rat Oral Acute Toxicity: | 0.889 | Maximum Recommended Daily Dose: | 0.881 |
Skin Sensitization: | 0.165 | Carcinogencity: | 0.778 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.319 |
Respiratory Toxicity: | 0.415 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004314 | 0.515 | D0Q0PR | 0.310 | ||||
ENC004145 | 0.496 | D0FX2Q | 0.258 | ||||
ENC002544 | 0.496 | D0F7CS | 0.245 | ||||
ENC002697 | 0.450 | D04ITO | 0.232 | ||||
ENC002341 | 0.430 | D06GCK | 0.232 | ||||
ENC002651 | 0.414 | D0J5TS | 0.225 | ||||
ENC002623 | 0.412 | D0H0SJ | 0.223 | ||||
ENC006093 | 0.366 | D0Z4PE | 0.223 | ||||
ENC002916 | 0.366 | D0T6WT | 0.221 | ||||
ENC004538 | 0.331 | D0O6KE | 0.220 |